28. Cockcroft D, Gault MH. Prediction of creatinine clearance from creatinine.Nephron. 1976; 16: 16-31.29. Schwartz GJ, Brion LP, Spitzer A. The use of plasma creatinine conc<strong>en</strong>trationfor estimating glomerular filtration rate in infants, childr<strong>en</strong> and adolesc<strong>en</strong>ts. PedClin N Amer, 1987; 34: 571-590.30. Medical Algorithms Project. http://www.medal.org. Visitado abril 2002.31. Clopés A. Dosificación de medicam<strong>en</strong>tos <strong>en</strong> insufici<strong>en</strong>cia r<strong>en</strong>al. En: Bonal J.Farmacia Clínica. Ed. Síntesis, Madrid. 1999; p: 391-401.32. Bates DW et al. Pot<strong>en</strong>tial id<strong>en</strong>tifiability and prev<strong>en</strong>tability of adverse ev<strong>en</strong>tsusing information systems. J Am Med Informatics Assoc. 1994; 1:404-411.33. Chertow GM et al. Guided medication dosing for pati<strong>en</strong>ts with r<strong>en</strong>alinsuffici<strong>en</strong>cy. JAMA 2001; 286: 2839-2844.34. Matzke GR, Millikin SP. Influ<strong>en</strong>ce of r<strong>en</strong>al function and dialysis on drugdisposition. En: Evans WE, Sch<strong>en</strong>tag JJ, Jusko WJ, Relling MV. AppliedPharmacokinetics: Principles of therapeutic drug monitoring. 3rd ed. Vancouver,WA Applied Therapeutics, Inc, 1992. p: 8-1-8-49.35. Keller F. Effect of plasma protein binding, volume of distribution and molecularweight on the fraction of drugs eliminated by hemodialysis. Clin Nephrol 1983;19: 201-205.36. Paton TW. Drug therapy in pati<strong>en</strong>t undergoing peritoneal dialysis. Clinicalpharmacokinetic considerations. Clin Pharmacokinetic 1985; 10: 404-26.37. Reetze-Bonord<strong>en</strong> P, Böhler J, Keller E. Drug dosage in pati<strong>en</strong>ts duringcontinuous r<strong>en</strong>al replacem<strong>en</strong>t therapy. Clin Pharmacokinet 1993; 24: 362-379.38. Armijo JA. Factores patológicos que condicionan la respuesta a los fármacos.En: Florez J. Farmacología humana 2th ed. Masson-Salvat. Barcelona, 1992:123-144.39. Kirchain WR and Gill MA. Acute hepatitis. En: DiPiro JT, Talbert RL, Yee GC ycols. Pharmacotherapy. 3rd ed. Appelton and Lange 1997, p: 801-814.40. Jim LK and Gree JP. Adverse effects of drugs on the liver. En: Young LY, Koda-Kimble MA. Applied Therapeutics: The clinical use of drugs 6th ed. Vancuver,WA Applied Therapeutics, inc 1995, p: 26-1 – 26-17.41. Ramos J. Hepatotoxicidad por medicam<strong>en</strong>tos. En: Bonal J. Farmacia Clínica.Ed. Síntesis, Madrid. 1999: 263-273.24
42. Di<strong>en</strong>stag JL and Issel Bacher KJ. Acute hepatitis. En: Isselbacher K, BraunwaldE. y cols. Harrison’s Principles of Internal Medicine 30 ed. USA Mc Graw-Hill Inc1994; p: 1458-1478.43. B<strong>en</strong>net WM. Guide to dosagein r<strong>en</strong>al failure. In Speight TM, Holford NHG.Avery's Drug treatm<strong>en</strong>t. 4 th Ed. Aukland, New Zealand. Adis International, 1997.44. Micromedex Healthcares Series, vol 111, expires 3-2002.45. Lacy C, Armstrong L, Ingrim N, Lance L. Drug Information Handbook 6 th Ed.Hudson American Pharmaceutical Association, 1998-99.46. Managem<strong>en</strong>t of the pati<strong>en</strong>t with r<strong>en</strong>al failure. In : Br<strong>en</strong>ner & Rector's. The Kidney6th ed. Boston: WB Saunders Company; 2000; section V: 2219-2654.47. M<strong>en</strong>sa J, Gatell JM, Jim<strong>en</strong>ez de Anta MT, Prats G, Dominguez-Gil A. Guíaterapéutica antimicrobiana 11ª ed. Barcelona: Masson SA. 2001.48. Parfitt K. Martindale. The Complete Drug Refer<strong>en</strong>ce. 32th ed. PharmaceuticalPress. 1999.25